Pharmaceuticals
Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee
-- Inclusion in the "Best of The Liver Meeting's Summary" is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB -- In patients with the baseline HBsAg level ≤ 500 IU/mL, the Phase IIb study demonstrated sustained HBsAg loss in 19...
2021-11-16 08:35
3566
Nanoform signs GMP agreement and achieves near-term business target
HELSINKI, Nov. 15, 2021 /PRNewswire/ -- Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling ...
2021-11-15 23:17
2243
R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved
BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...
2021-11-15 22:47
3393
Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium
TAIPEI and SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting clinical design for their lead drug candidate...
2021-11-15 20:00
2308
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention
JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding
Group Limited (Nasdaq: QLI
2021-11-15 20:00
1823
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...
2021-11-15 20:00
4425
Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing
SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....
2021-11-15 19:00
2318
Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...
2021-11-15 08:30
3470
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-11-15 08:00
3707
Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...
2021-11-13 02:56
5357
Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China
SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...
2021-11-12 14:17
2465
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to share company's latest development. Details are as follows: ...
2021-11-12 14:14
2279
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
MINSK, Belarus, Nov. 12, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New
Era Biotechnology Co., Ltd. participated in the fourth edition of the China
International Import Expo (CIIE) which opened inShanghai on November 5, 2021.
2021-11-12 09:11
2881
Hetero and Shenzhen Beimei Pharmaceuticals launch antiviral drug Oselavir® in China
Oseltamivir phosphate is used in the treatment of acute uncomplicated influenza infection in adults, adolescents and children BEIJING, Nov. 12, 2021 /PRNewswire/ -- Hetero, a globally renowned vertically integrated pharmaceutical organization and Shenzhen Beimei Pharmaceuticals jointly announced...
2021-11-12 09:00
4183
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...
2021-11-12 07:55
4252
PNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at theUniversity of Calif...
2021-11-11 21:00
3546
Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose, placeab...
2021-11-11 18:00
1970
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announces today that Everest Medicines sponsored (HKEX 1952.HK) Phase2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint o...
2021-11-11 08:05
4401
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed
* Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). * Dosimetry data is be...
2021-11-10 22:06
2651
IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021
SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 10, 2021 /PRNewswire/ --
IASO Biotherapeutics("IASO Bio")
2021-11-10 21:30
2162
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 322 media titles]
2026-07-24 12:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 298 media titles]
2026-07-23 16:00
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 295 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 290 media titles]
2026-07-24 16:25
CityUHK researchers transform vibrations into clean fuels and chemicals through piezosynthesis
[Picked up by 287 media titles]
2026-07-24 17:11
Most Read
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
2026-07-23 16:00
11454
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
2026-07-24 12:00
10869
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
2026-07-24 18:32
10195
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
2026-07-24 16:25
9006